Naturally-occurring human enzymes are among the most important agents for a wide variety of vital functions in the body. BioMarin's unique products will expand the range of enzyme therapies and accelerate their role in medicine. Two of BioMarin's products can be expected to be FDA-approved in the next 24 months, and one additional product shortly thereafter. Technology BioMarin's core technology is derived from the successful rapid cloning of carbohydrate-acting enzymes and the proprietary protein expression technology developed by Glyko and the Management.
Enzymes have an important role in treatment of disease and have many advantages over other drugs.
The Company has already been successful at producing a number of unique pure natural protein enzymes by recombinant means. BioMarin's proprietary technology will yield therapeutically-significant patented therapies having low production costs and high purity levels. Production has been in sufficient quantities to proceed directly to pre-clinical and clinical trials. The selection of initial product targets for the Company was preceded by a thorough strategic review of approximately 30 disease candidates for which BioMarin had identified potential therapies. Five initial projects have been selected for accelerated development based on uniqueness of therapeutic approach, degree of un-met medical need, speed to market approval and the size of commercial potential.